Amgen is a multinational biopharmaceutical company that specialises in the development and manufacturing of innovative therapies to treat serious illnesses.
The company is focused on using advanced biotechnology and scientific research to address some of the most complex medical conditions, including cancer, cardiovascular disease, kidney disease, inflammatory diseases, and bone disorders.
As a health care stock the company can potentially weather any tougher US financial conditions that may be ahead. This is because even during a recession health care needs are still prioritised supporting health care stocks.
Over the last 20 years Amgen’s share price has risen 85% of the time between May 31 and July 29 with an average return of 9.14% and an annualised return of over 72%. So, in the face of worries over a looming US recession is Amgen a health care stock worth considering?
Major Trade Risks:
The biggest risk here is if the US debt ceiling talks fail to get passed by Congress in time as this will likely sharply weaken US stocks.
Remember, don’t just trade it, Seasonax it!